PREVENTION OF STROKE IN ATRIAL FIBRILLATION: THE APPROACHES TO THE CHOICE OF ANTICOAGULANT, DEPENDING ON AGE

Abstract

SUMMERY The main objective of the management of patients with atrial fibrillation (AF) is an effective prevention of ischemic stroke. For this purpose indirect and direct oral anticoagulants may be used. The choice of anticoagulant should be based on a comprehensive assessment of a number of factors - the presence of significant valvular disease, kidney function, potential drug interactions, risk of complications of anticoagulant therapy. Individual assessment of the profile of thromboembolic and hemorrhagic risks are largely determined by the age, can help choose an efficient anticoagulant with minimal risk of complications. In patients younger than 75 years, in the absence of contraindications to the use of direct oral anticoagulants, the drug of choice can be dabigatran, administered at a dose of 150 mg 2 b.i.d. Keywords: prevention of stroke, atrial fibrillation, cardiovascular disease, new oral anticoagulants.